Single User License
INR 135120
Site License
INR 270240
Corporate User License
INR 405360

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Cognitive Impairment-Pipeline Review, H1 2015

Cognitive Impairment-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Cognitive Impairment-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Cognitive Impairment-Pipeline Review, H1 2015', provides an overview of the Cognitive Impairment's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Cognitive Impairment and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Cognitive Impairment pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Cognitive Impairment pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Cognitive Impairment Overview 11

Therapeutics Development 12

Pipeline Products for Cognitive Impairment-Overview 12

Pipeline Products for Cognitive Impairment-Comparative Analysis 13

Cognitive Impairment-Therapeutics under Development by Companies 14

Cognitive Impairment-Therapeutics under Investigation by Universities/Institutes 19

Cognitive Impairment-Pipeline Products Glance 20

Late Stage Products 20

Clinical Stage Products 21

Early Stage Products 22

Cognitive Impairment-Products under Development by Companies 23

Cognitive Impairment-Products under Investigation by Universities/Institutes 29

Cognitive Impairment-Companies Involved in Therapeutics Development 30

AbbVie Inc. 30

Addex Therapeutics Ltd 31

AGY Therapeutics, Inc. 32

Amarantus Bioscience Holdings, Inc. 33

AstraZeneca PLC 34

Avineuro Pharmaceuticals, Inc. 35

Boehringer Ingelheim GmbH 36

Bristol-Myers Squibb Company 37

Cardax Pharmaceuticals, Inc. 38

CoMentis, Inc. 39

D-Pharm Ltd. 40

Dart NeuroScience LLC 41

Eisai Co., Ltd. 42

Eli Lilly and Company 43

Evotec AG 44

F. Hoffmann-La Roche Ltd. 45

FORUM Pharmaceuticals Inc. 46

H. Lundbeck A/S 47

Heptares Therapeutics Ltd. 48

Intra-Cellular Therapies, Inc. 49

Iproteos S.L. 50

Merck & Co., Inc. 51

Mithridion, Inc. 52

Mnemosyne Pharmaceuticals, Inc. 53

Neuralstem, Inc. 54

Novartis AG 55

Octapharma AG 56

Omeros Corporation 57

Pacific Northwest Biotechnology, LLC 58

Panacea Pharmaceuticals, Inc. 59

Pfizer Inc. 60

Pherin Pharmaceuticals, Inc. 61

Sage Therapeutics 62

Saniona AB 63

Sanofi 64

Shire Plc 65

Siena Biotech S.p.A. 66

SK Biopharmaceuticals Co., Ltd. 67

Sunovion Pharmaceuticals Inc. 68

Suven Life Sciences Ltd. 69

Takeda Pharmaceutical Company Limited 70

Teva Pharmaceutical Industries Limited 71

Theratechnologies Inc. 72

Upsher-Smith Laboratories, Inc. 73

Vicore Pharma AB 74

Virogenomics, Inc. 75

Cognitive Impairment-Therapeutics Assessment 76

Assessment by Monotherapy Products 76

Assessment by Target 77

Assessment by Mechanism of Action 80

Assessment by Route of Administration 83

Assessment by Molecule Type 85

Drug Profiles 87

2-PMPA-Drug Profile 87

A-431404-Drug Profile 88

ADX-92639-Drug Profile 89

AN-761-Drug Profile 90

AP-61-Drug Profile 91

AQW-051-Drug Profile 92

AUT-1-Drug Profile 93

AUT-6-Drug Profile 94

AUT-9-Drug Profile 95

AVL-3288-Drug Profile 96

AVN-211-Drug Profile 97

BAN-2401-Drug Profile 98

BCA-909-Drug Profile 100

BI-409306-Drug Profile 102

BMS-933043-Drug Profile 103

BNC-375-Drug Profile 104

C-21-Drug Profile 105

CDD-0304-Drug Profile 107

CDX-085-Drug Profile 109

CSP-1103-Drug Profile 111

DAOI-B-Drug Profile 113

DP-NDD-Drug Profile 114

Drug to Agonize Muscarinic M1/M4 Receptors for Psychosis and Cognitive Impairment-Drug Profile 115

Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment-Drug Profile 116

DSP-3748-Drug Profile 117

E-1R-Drug Profile 118

eltoprazine-Drug Profile 119

encenicline hydrochloride-Drug Profile 121

erteberel-Drug Profile 124

EVT-501-Drug Profile 125

FRM-0962-Drug Profile 126

GTS-21-Drug Profile 127

HTL-9936-Drug Profile 129

idursulfase-Drug Profile 130

immune globulin (human)-Drug Profile 131

IPR-001-Drug Profile 133

IPR-088-Drug Profile 134

IPR-19-Drug Profile 135

irdabisant-Drug Profile 136

ITI-214-Drug Profile 137

ladostigil tartrate-Drug Profile 138

levetiracetam-Drug Profile 140

LUAF-64280-Drug Profile 141

LY-3002813-Drug Profile 142

NS-9283-Drug Profile 143

NSI-189-Drug Profile 145

PAN-811-Drug Profile 146

Peptide T-Drug Profile 148

PF-04958242-Drug Profile 149

PH-15-Drug Profile 150

PNU-120596-Drug Profile 151

RO-4938581-Drug Profile 152

roflumilast-Drug Profile 153

RTL-551-Drug Profile 156

SAGE-547-Drug Profile 157

SAR-228810-Drug Profile 159

SEN-15924-Drug Profile 160

SKL-15508-Drug Profile 161

Small Molecule 1 for Cognitive Impairment-Drug Profile 162

Small Molecule 10 for Cognitive Impairment-Drug Profile 163

Small Molecule 11 for Cognitive Impairment-Drug Profile 164

Small Molecule 12 for Cognitive Impairment-Drug Profile 165

Small Molecule 2 for Cognitive Impairment-Drug Profile 166

Small Molecule 3 for Cognitive Impairment-Drug Profile 167

Small Molecule 4 for Cognitive Impairment-Drug Profile 168

Small Molecule 5 for Cognitive Impairment-Drug Profile 169

Small Molecule 6 for Cognitive Impairment-Drug Profile 170

Small Molecule 7 for Cognitive Impairment-Drug Profile 171

Small Molecule 8 for Cognitive Impairment-Drug Profile 172

Small Molecule to Agonize Neuronal Acetylcholine Receptor Subunit Alpha-7 for Central Nervous System-Drug Profile 173

Small Molecule to Agonize NMDA2B for CIAS-Drug Profile 174

Small Molecule to Antagonize GPR12 for Obesity, Cognitive Impairments and Motor Disorders-Drug Profile 176

Small Molecule to Antagonize Histamine 3 Receptor for Cognition-Drug Profile 177

Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for CNS Disorders-Drug Profile 178

Small Molecule to Inhibit Tyrosine Phosphatase for Cognition and Schizophrenia-Drug Profile 179

Small Molecule to Target GPR151 for CNS Diseases-Drug Profile 180

Small Molecule to Target MAS1 for Cognitive Impairments, Blood Pressure Abnormalities and Colon Cancer-Drug Profile 181

Small Molecules for Cognitive Impairment Associated with Schizophrenia-Drug Profile 182

Small Molecules to Agonize 5-HT4 Receptors for Cognitive Impairment-Drug Profile 183

Small Molecules to Agonize Beta-1 Adrenergic Receptor for Cognitive Impairment-Drug Profile 184

Small Molecules to Agonize GABAA Receptor for Cognitive Impairment-Drug Profile 185

Small Molecules to Agonize nAChR for Alzheimer's Disease and Cognitive Impairment-Drug Profile 186

Small Molecules to Antagonize 5-HT6 Receptors for Cognitive Impairment-Drug Profile 188

Small Molecules to Inhibit Tyrosine Phosphatase for Cognition and Schizophrenia-Drug Profile 189

Stem Cell Therapy for Cognitive Impairment-Drug Profile 190

SUVN-501-Drug Profile 191

SUVN-901-Drug Profile 192

SUVN-976-Drug Profile 193

SUVN-D-1108121-Drug Profile 194

TAK-058-Drug Profile 195

tesamorelin acetate-Drug Profile 196

tropisetron hydrochloride-Drug Profile 199

VU-0092273-Drug Profile 200

xamoterol fumarate-Drug Profile 201

Cognitive Impairment-Recent Pipeline Updates 202

Cognitive Impairment-Dormant Projects 224

Cognitive Impairment-Discontinued Products 230

Cognitive Impairment-Product Development Milestones 231

Featured News & Press Releases 231

Appendix 236

Methodology 236

Coverage 236

Secondary Research 236

Primary Research 236

Expert Panel Validation 236

Contact Us 236

Disclaimer 237

List of Tables

Number of Products under Development for Cognitive Impairment, H1 2015 18

Number of Products under Development for Cognitive Impairment-Comparative Analysis, H1 2015 19

Number of Products under Development by Companies, H1 2015 21

Number of Products under Development by Companies, H1 2015 (Contd..1) 22

Number of Products under Development by Companies, H1 2015 (Contd..2) 23

Number of Products under Development by Companies, H1 2015 (Contd..3) 24

Number of Products under Investigation by Universities/Institutes, H1 2015 25

Comparative Analysis by Late Stage Development, H1 2015 26

Comparative Analysis by Clinical Stage Development, H1 2015 27

Comparative Analysis by Early Stage Development, H1 2015 28

Products under Development by Companies, H1 2015 29

Products under Development by Companies, H1 2015 (Contd..1) 30

Products under Development by Companies, H1 2015 (Contd..2) 31

Products under Development by Companies, H1 2015 (Contd..3) 32

Products under Development by Companies, H1 2015 (Contd..4) 33

Products under Development by Companies, H1 2015 (Contd..5) 34

Products under Investigation by Universities/Institutes, H1 2015 35

Cognitive Impairment-Pipeline by AbbVie Inc., H1 2015 36

Cognitive Impairment-Pipeline by Addex Therapeutics Ltd, H1 2015 37

Cognitive Impairment-Pipeline by AGY Therapeutics, Inc., H1 2015 38

Cognitive Impairment-Pipeline by Amarantus Bioscience Holdings, Inc., H1 2015 39

Cognitive Impairment-Pipeline by AstraZeneca PLC, H1 2015 40

Cognitive Impairment-Pipeline by Avineuro Pharmaceuticals, Inc., H1 2015 41

Cognitive Impairment-Pipeline by Boehringer Ingelheim GmbH, H1 2015 42

Cognitive Impairment-Pipeline by Bristol-Myers Squibb Company, H1 2015 43

Cognitive Impairment-Pipeline by Cardax Pharmaceuticals, Inc., H1 2015 44

Cognitive Impairment-Pipeline by CoMentis, Inc., H1 2015 45

Cognitive Impairment-Pipeline by D-Pharm Ltd., H1 2015 46

Cognitive Impairment-Pipeline by Dart NeuroScience LLC, H1 2015 47

Cognitive Impairment-Pipeline by Eisai Co., Ltd., H1 2015 48

Cognitive Impairment-Pipeline by Eli Lilly and Company, H1 2015 49

Cognitive Impairment-Pipeline by Evotec AG, H1 2015 50

Cognitive Impairment-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 51

Cognitive Impairment-Pipeline by FORUM Pharmaceuticals Inc., H1 2015 52

Cognitive Impairment-Pipeline by H. Lundbeck A/S, H1 2015 53

Cognitive Impairment-Pipeline by Heptares Therapeutics Ltd., H1 2015 54

Cognitive Impairment-Pipeline by Intra-Cellular Therapies, Inc., H1 2015 55

Cognitive Impairment-Pipeline by Iproteos S.L., H1 2015 56

Cognitive Impairment-Pipeline by Merck & Co., Inc., H1 2015 57

Cognitive Impairment-Pipeline by Mithridion, Inc., H1 2015 58

Cognitive Impairment-Pipeline by Mnemosyne Pharmaceuticals, Inc., H1 2015 59

Cognitive Impairment-Pipeline by Neuralstem, Inc., H1 2015 60

Cognitive Impairment-Pipeline by Novartis AG, H1 2015 61

Cognitive Impairment-Pipeline by Octapharma AG, H1 2015 62

Cognitive Impairment-Pipeline by Omeros Corporation, H1 2015 63

Cognitive Impairment-Pipeline by Pacific Northwest Biotechnology, LLC, H1 2015 64

Cognitive Impairment-Pipeline by Panacea Pharmaceuticals, Inc., H1 2015 65

Cognitive Impairment-Pipeline by Pfizer Inc., H1 2015 66

Cognitive Impairment-Pipeline by Pherin Pharmaceuticals, Inc., H1 2015 67

Cognitive Impairment-Pipeline by Sage Therapeutics, H1 2015 68

Cognitive Impairment-Pipeline by Saniona AB, H1 2015 69

Cognitive Impairment-Pipeline by Sanofi, H1 2015 70

Cognitive Impairment-Pipeline by Shire Plc, H1 2015 71

Cognitive Impairment-Pipeline by Siena Biotech S.p.A., H1 2015 72

Cognitive Impairment-Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 73

Cognitive Impairment-Pipeline by Sunovion Pharmaceuticals Inc., H1 2015 74

Cognitive Impairment-Pipeline by Suven Life Sciences Ltd., H1 2015 75

Cognitive Impairment-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 76

Cognitive Impairment-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 77

Cognitive Impairment-Pipeline by Theratechnologies Inc., H1 2015 78

Cognitive Impairment-Pipeline by Upsher-Smith Laboratories, Inc., H1 2015 79

Cognitive Impairment-Pipeline by Vicore Pharma AB, H1 2015 80

Cognitive Impairment-Pipeline by Virogenomics, Inc., H1 2015 81

Assessment by Monotherapy Products, H1 2015 82

Number of Products by Stage and Target, H1 2015 84

Number of Products by Stage and Mechanism of Action, H1 2015 87

Number of Products by Stage and Route of Administration, H1 2015 90

Number of Products by Stage and Molecule Type, H1 2015 92

Cognitive Impairment Therapeutics-Recent Pipeline Updates, H1 2015 208

Cognitive Impairment-Dormant Projects, H1 2015 230

Cognitive Impairment-Dormant Projects (Contd..1), H1 2015 231

Cognitive Impairment-Dormant Projects (Contd..2), H1 2015 232

Cognitive Impairment-Dormant Projects (Contd..3), H1 2015 233

Cognitive Impairment-Dormant Projects (Contd..4), H1 2015 234

Cognitive Impairment-Dormant Projects (Contd..5), H1 2015 235

Cognitive Impairment-Discontinued Products, H1 2015 236

List of Figures

Number of Products under Development for Cognitive Impairment, H1 2015 18

Number of Products under Development for Cognitive Impairment-Comparative Analysis, H1 2015 19

Number of Products under Development by Companies, H1 2015 20

Number of Products under Investigation by Universities/Institutes, H1 2015 25

Comparative Analysis by Clinical Stage Development, H1 2015 27

Comparative Analysis by Early Stage Products, H1 2015 28

Assessment by Monotherapy Products, H1 2015 82

Number of Products by Top 10 Targets, H1 2015 83

Number of Products by Stage and Top 10 Targets, H1 2015 83

Number of Products by Top 10 Mechanism of Actions, H1 2015 86

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 86

Number of Products by Top 10 Routes of Administration, H1 2015 89

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 90

Number of Products by Top 10 Molecule Types, H1 2015 91

Number of Products by Stage and Top 10 Molecule Types, H1 2015 91

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Addex Therapeutics Ltd

AGY Therapeutics, Inc.

Amarantus Bioscience Holdings, Inc.

AstraZeneca PLC

Avineuro Pharmaceuticals, Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Cardax Pharmaceuticals, Inc.

CoMentis, Inc.

D-Pharm Ltd.

Dart NeuroScience LLC

Eisai Co., Ltd.

Eli Lilly and Company

Evotec AG

F. Hoffmann-La Roche Ltd.

FORUM Pharmaceuticals Inc.

H. Lundbeck A/S

Heptares Therapeutics Ltd.

Intra-Cellular Therapies, Inc.

Iproteos S.L.

Merck & Co., Inc.

Mithridion, Inc.

Mnemosyne Pharmaceuticals, Inc.

Neuralstem, Inc.

Novartis AG

Octapharma AG

Omeros Corporation

Pacific Northwest Biotechnology, LLC

Panacea Pharmaceuticals, Inc.

Pfizer Inc.

Pherin Pharmaceuticals, Inc.

Sage Therapeutics

Saniona AB

Sanofi

Shire Plc

Siena Biotech S.p.A.

SK Biopharmaceuticals Co., Ltd.

Sunovion Pharmaceuticals Inc.

Suven Life Sciences Ltd.

Takeda Pharmaceutical Company Limited

Teva Pharmaceutical Industries Limited

Theratechnologies Inc.

Upsher-Smith Laboratories, Inc.

Vicore Pharma AB

Virogenomics, Inc.

Cognitive Impairment Therapeutic Products under Development, Key Players in Cognitive Impairment Therapeutics, Cognitive Impairment Pipeline Overview, Cognitive Impairment Pipeline, Cognitive Impairment Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com